



Raymed Labs Ltd.

Manufacturers of Allopathic Medicines

CIN: L24111UP1992PLC014240

REGISTERED OFFICE,

703, ASTER 7, SUPERTECH EMERALD COURT, SECTOR-93A, NOIDA-201304 (U.P.)

e-mail : raymedlabs@rediffmail.com website : www.raymedlab.com

Tel. 0120-2426900, 9412700300

12th November 2016

The Manager – Listing
The Department of Corporate Services

BSE Limited

Phiroze Jeejeebhoy Towers

Dalal Street, Fort

Mumbai – 400001

BSE Scrip Code: 531207

Subject: Outcome of Board Meeting under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam:

We would like to inform you that the Board of Directors at their meeting held today i.e. Saturday, November 12, 2016 has inter alia approved the following resolutions:

1. The Board considered and approved Unaudited Financial Results including the Statement of Assets & Liabilities as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter ending on September 30th 2016.
2. The Board took note of the Limited Review Report as per Annexure V of Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 as placed by the Auditor.
3. The Board took note of Statement of Investor Complaints/Grievances given Under Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 for the quarter ending on September 30th 2016.

We hope you will find the same in order.

Kindly take the above information on your records.

Thanking you,

Sincerely,

For Raymed Labs Limited

Ajai Goyal

Whole Time Director

DIN: 02636418

CC: Ahmedabad Stock Exchange Limited

Raymed Labs Limited

Regd. Office: 703 Aster 7, Supertech Emerald Court, Sector 93A, Noida - 201304, Uttar Pradesh, CIN: L24111UP1992PLC014240

E-Mail: raymedlabs@rediffmail.com, Website: www.raymedlab.com, Tel: 0120-2426900, 9412700300

Un-audited Financial Results for the Quarter Ended on September 30, 2016

PART I							Rs. in Lacs
	Particulars	3 Months Ended	Preceding 3 Months Ended	Corresponding 3 Months in the Previous Year Ended	Year to Date Figures for Current Period Ended	Year to Date Figures for the Previous Year Ended	Previous Year Ended
		30-09-2016	30-06-2016	30-09-2015	30-09-2016	30-09-2015	31-03-2016
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from Operations						
	(a) Net Sales / Income from Operations (Net of excise duty)	-	-	-	-	-	-
	(b) Other Operating Income	-	-	-	-	-	-
	Total Income from Operations (net)	-	-	-	-	-	-
2	Expenses						
	(a) Cost of materials consumed	-	-	-	-	-	-
	(b) Purchase of stock-in-trade	-	-	-	-	-	-
	Changes in inventories of finished goods,						
	(c) work-in-progress and stock-in-trade	-	-	-	-	-	-
	(d) Employee expenses & benefits	0.23	0.59	0.23	0.81	0.45	0.90
	(e) Depreciation and amortisation expense	0.22	0.22	-	0.44	-	0.89
	(f) Other expenses	0.57	0.40	0.67	0.98	1.23	1.63
	Total Expenses	1.02	1.21	0.90	2.23	1.68	3.42
3	Profit/(Loss) from Operations before other Income, Finance costs and Exceptional Items (1-2)	-1.02	-1.21	-0.90	-2.23	-1.68	-3.42
4	Other Income	0.30	0.30	0.54	0.60	1.08	1.92
5	Profit/Loss from ordinary activities before finance costs and exceptional Items (3+4)	-0.72	-0.91	-0.36	-1.63	-0.60	-1.50
6	Finance Costs	-	-	-	-	-	-
7	Profit/Loss from ordinary activities after finance costs but before exceptional items (5-6)	-0.72	-0.91	-0.36	-1.63	-0.60	-1.50
8	Exceptional Items	-	2.29	-	2.29	-	2.25
9	Profit/Loss from Ordinary Activities before tax (7-8)	-0.72	-3.20	-0.36	-3.92	-0.60	-3.75
10	Tax Expense	-	-	-	-	-	-
11	Net Profit/ Loss from Ordinary Activities after Tax (9-10)	-0.72	-3.20	-0.36	-3.92	-0.60	-3.75
12	Extraordinary Item (net of tax expense)	-	-	-	-	-	-
13	Net Profit/ Loss for the period (11-12)	-0.72	-3.20	-0.36	-3.92	-0.60	-3.75
17	Paid up Equity Share Capital (Face Value Rs.10/- per share)	427.35	427.35	427.35	427.35	427.35	427.35
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	-
19 i	Earning Per Share (before extraordinary items)	-0.017	-0.075	-0.008	-0.092	-0.014	-0.088
19 ii	Earning Per Share (after extraordinary items)	-0.017	-0.075	-0.008	-0.092	-0.014	-0.088

Notes

(1) The above results have been reviewed by Audit Committee and taken on record by the Board of Directors at its Meeting held on 12.11.2016. The Statutory Auditors have carried out a Limited Review of the above results.

(2) Segment reporting as defined in Accounting Standard (AS-17) is not applicable since the entire operation of the company relates to only one segment.

(3) In terms of Regulation 13(3) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, there were no investor complaint pending at the beginning of the quarter or lying unresolved at 30.09.2016

(4) The figures have been re-grouped/re-arranged wherever considered necessary.

For Raymed Labs Limited



Ajai Goyal
Whole Time Director
DIN: 02636418
Place: NOIDA

Date: 12-11-2016

Raymed Labs Limited

Regd. Office: 703 Aster 7, Supertech Emerald Court, Sector 93A, Noida - 201304, Uttar Pradesh, CIN: L24111UP1992PLC014240
E-Mail: raymedlabs@rediffmail.com, Website: www.raymedlab.com, Tel: 0120-2426900, 9412700300

Statement of Assets and Liabilities

Rs. in Lacs

Particulars	As at 30-09-2016	As at 31-03-2016
	Un-audited	Audited
A EQUITY AND LIABILITIES		
1 Shareholders' Funds		
(a) Share Capital	427.35	427.35
(b) Reserves and Surplus	-608.08	-604.17
(c) Money Received Against Share Warrants	-	-
Sub-total - Shareholders' Funds	-180.73	-176.82
2 Share Application Money Pending Allotment		
3 Minority Interest		
4 Non-Current Liabilities		
(a) Long-Term Borrowings	-	-
(b) Deferred Tax Liabilities (net)	-	-
(c) Other Long-Term Liabilities	-	-
(d) Long-Term Provisions	-	-
Sub-total - Non-Current Liabilities	-	-
5 Current Liabilities		
(a) Short-Term Borrowings	197.50	198.60
(b) Trade Payables	3.89	-
(c) Other Current Liabilities	2.39	6.15
(d) Short-Term Provisions	5.00	-
Sub-total - Current Liabilities	208.78	204.75
TOTAL - EQUITY AND LIABILITIES	28.05	27.93
B ASSETS		
1 Non-Current Assets		
(a) Fixed Assets	18.87	19.31
(b) Goodwill on Consolidation	-	-
(c) Non-current Investments	-	-
(d) Deferred Tax Assets (net)	-	-
(e) Long-term Loans and Advances	-	-
(f) Other Non-current Assets	-	-
Sub-total - Non-Current Assets	18.87	19.31
2 Current Assets		
(a) Current Investments	-	-
(b) Inventories	-	-
(c) Trade Receivables	2.49	2.49
(d) Cash and Cash Equivalents	0.16	0.03
(e) Short-term Loans and Advances	0.45	-
(f) Other Current Assets	6.08	6.10
Sub-total - Current Assets	9.18	8.62
TOTAL - ASSETS	28.05	27.93

For Raymed Labs Limited



Ajai Goyal
Whole Time Director
DIN: 02636418

Place: NOIDA
Date: 12-11-2016



A.Kay Mehra & Co.

CHARTERED ACCOUNTANTS

114 (Basement), Mall Road, Kingsway Camp, Delhi-110009

Tel. No. : 011-42461274, 9891295255

E-mail : akmca1969@gmail.com Website : www.akmca.in

To
The Board of Directors
Raymed Labs Limited
703, Aster 7, Supertech Emerald Court,
Sector 93A, Noida - 201304

Limited Review Report for the quarter ended September 30, 2016

We have reviewed the accompanying statement of unaudited financial results of **Raymed Labs Limited** for the period ended September 30, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A.Kay Mehra & Co.
Chartered Accountants


Deepak Suneja
Partner

Membership No. : 501957

Firm Registration No. : 050004C

Date: 12.11.2016

Place: New Delhi

HEAD OFFICE : 120/128, LAJPAT NAGAR, KANPUR-208 005, PH. No. : 0512-2240909, 9956358976

BRANCH OFFICES : 114,(BASEMENT) MALL ROAD, KINGSWAY CAMP, DELHI-110009 & C-32, SECTOR-14, NOIDA-201301